Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SGMS1 | Q86VZ5 | 2/20 | 0.34 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | METAP1 | P53582 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628034 | 0.88 | SLC6A2 (0.35) | KCNA5SMN1; SMN2SGMS1SGMS2 | |
| SCHEMBL2633191 | 0.85 | KCNA5 (0.56) | KCNA5SGMS1SGMS2 | |
| SCHEMBL1478346 | 0.75 | KCNA5 (0.47) | KCNA5SMN1; SMN2SGMS1SGMS2 | |
| SCHEMBL1478328 | 0.69 | KCNA5 (0.48) | KCNA5LMNASMN1; SMN2SGMS1SGMS2 | |
| SCHEMBL1478103 | 0.68 | KCNA5 (0.61) | KCNA5SGMS1SGMS2 | |
| SCHEMBL1478104 | 0.68 | KCNA5 (0.61) | KCNA5SGMS1SGMS2 | |
| SCHEMBL1478152 | 0.68 | KCNA5 (0.61) | KCNA5SGMS1SGMS2 | |
| SCHEMBL12426072 | 0.67 | SGMS2 (0.39) | KCNA5SMN1; SMN2SGMS1SGMS2ELANE | |
| SCHEMBL2628031 | 0.65 | KCNA5 (0.54) | KCNA5SGMS1SGMS2TSHRHSD17B10 | |
| SCHEMBL3613003 | 0.64 | MTNR1A (0.49) | SMN1; SMN2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357809-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | KCNH2, KCNJ2, KCNH3 | KCNA5 67/4885LMNA 2461/4885HPGD 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.